rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

PR GTC 20/9/05

10 Posts
| Omlaag ↓
  2. frederic_knight 20 september 2005 14:42

    • frederic_knight

      Lid sinds: 04 okt 2004

      Laatste bezoek: 11 apr 2023

    • Aanbevelingen

      Ontvangen: 14

      Gegeven: 12

    •    Aantal posts: 64

    GTC BIOTHERAPEUTICS ENTERS AGREEMENT FOR FURTHER CLINICAL PRODUCTION OF MM-093 FOR MERRIMACK PHARMACEUTICALS

    FRAMINGHAM, MA – September 20, 2005 -- GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that it has entered into an agreement for further production of MM-093 for Merrimack Pharmaceuticals, Inc. MM-093, Merrimack’s lead clinical product, is a recombinant version of human alpha-fetoprotein. Merrimack is conducting a Phase II study of MM-093 in patients with rheumatoid arthritis and is planning additional clinical studies.


    “We are pleased to continue to support Merrimack’s supply needs for their clinical studies of MM-093,” stated Gregory Liposky, GTC’s Senior Vice President of Operations. “GTC’s technology is a cost-effective production method for recombinant proteins and is well suited for the production of Merrimack’s human alpha-fetoprotein.”



    About Merrimack Pharmaceuticals

    Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer. Its lead compound, MM-093, is currently in clinical development to treat patients with rheumatoid arthritis. MM-093 is an investigational drug and has not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics.

    Merrimack is a privately held company based in Cambridge, Massachusetts. For additional information, please visit www.merrimackpharma.com.

    About GTC Biotherapeutics, Inc.

    GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC currently has five products in its internal pipeline and a portfolio of external program production opportunities. GTC's lead program is ATryn®, its recombinant form of human antithrombin. A Market Authorization Application is under review by the European Medicines Agency for the use of ATryn® in patients with a hereditary antithrombin deficiency. In addition to the lead ATryn® program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a malaria vaccine, and a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. Additional information is available on the GTC web site, www.gtc-bio.com.



    This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding continuing clinical studies of MM-093 and GTC’s role in producing further supplies. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, the risks and uncertainties discussed in GTC's most recent Annual Report on Form 10-K and its other periodic reports as filed with the Securities and Exchange Commission, including the uncertainties associated with conducting clinical studies, and the risks and uncertainties associated with dependence upon the actions of partners. GTC cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and GTC undertakes no obligation to update or revise the statements, except as may be required by law.



    CONTACT:
    GTC Biotherapeutics, Inc.
    Thomas E. Newberry
    Vice President, Corporate Communications
    US (508) 370-5374



    Feinstein Kean Healthcare for GTC Biotherapeutics, Inc.
    Francesca DeVellis
    US (617) 577-8110

    If you wish to be removed from this distribution list, please reply to this email with "REMOVE" in the subject line.

  4. gvanmaarsum 20 september 2005 15:12

    • gvanmaarsum

      Lid sinds: 01 jan 2000

      Laatste bezoek: 11 feb 2025

    • Aanbevelingen

      Ontvangen: 426

      Gegeven: 104

    •    Aantal posts: 857

    quote:

    killer_forehand schreef:

    Hebben klein maandje geleden ofzo ook al zo'n award gewonnen, meen ik. Koers deed toen niet zoveel.
    Bericht niet gelezen? Dit gaat niet om een Award.
  6. [verwijderd] 20 september 2005 15:20

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    We are pleased to continue to support Merrimack’s supply needs for their clinical studies of MM-093

    wil zeggen dat het gewoon over een voortgezette samenwerking gaat
    zoveel nieuws is dat niet zeker?
    Compu
10 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.003
AB InBev 2 5.486
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.273
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.555
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.657
Aedifica 3 902
Aegon 3.258 322.677
AFC Ajax 538 7.087
Affimed NV 2 6.288
ageas 5.844 109.887
Agfa-Gevaert 14 2.048
Ahold 3.538 74.302
Air France - KLM 1.025 35.008
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.370
Allfunds Group 4 1.469
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.819
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 242.822
AMG 971 133.147
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 485
Antonov 22.632 153.605
Aperam 92 14.960
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.733
Arcelor Mittal 2.033 320.620
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.724
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.087
ASML 1.766 106.207
ASR Nederland 21 4.452
ATAI Life Sciences 1 7
Atenor Group 1 484
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.639
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392